https://www.selleckchem.com/pr....oducts/Tranilast.htm
-LONG was similar to that of rIX-FP-treated patients from PROLONG-9FP and, therefore, indicates that the two EHL therapies provide similar efficacy when used as prophylaxis for patients with hemophilia B. Trough levels differ between the two products (1-3% [targeted] versus 20% [observed], respectively), suggesting that trough level is not a surrogate indicator when ABR is used as a criterion for clinical efficacy when comparing these FIX products in hemophilia B.The EGFR exon 20 insertion (EGFRex20ins) mutations are the third most co
Beğen
Yorum Yap
Paylaş
